Skip to content
    Real-World Studies

    Allogeneic Stem Cell Transplantation Outcomes in North American Adult T-Cell Leukemia/Lymphoma

    Wang et alTransplantation and cellular therapy

    Allogeneic Stem Cell Transplantation Outcomes in North American Adult T-Cell Leukemia/Lymphoma
    In a multicenter retrospective registry study evaluating 46 adult patients with North American adult T-cell leukemia/lymphoma (NA-ATLL), researchers assessed clinical outcomes following allogeneic hematopoietic cell transplantation (HCT). NA-ATLL disproportionately affects individuals of Afro-Caribbean and Latin American descent, who often face barriers identifying 8/8 HLA-matched donors. Within the cohort, myeloablative conditioning was used in 21.7% of patients, and 54.3% received alternative donor grafts without a matched donor.
    The primary analysis revealed no significant difference in overall survival (OS, p = 0.601) or progression-free survival (PFS, p = 0.376) between recipients of matched versus alternative donor HCT. However, disease subtype markedly influenced survival: patients with acute disease experienced significantly inferior OS compared to those with lymphomatous disease (log-rank p = 0.043; 3-year OS of 22.2% vs 52.3%, respectively). Multivariable Cox proportional hazards regression identified lymphomatous subtype (HR 0.30, 95% CI 0.10–0.88, p = 0.027) and a baseline Karnofsky performance score of 80 or higher (HR 0.26, 95% CI 0.09–0.73, p = 0.01) as significant independent predictors of improved OS.
    Post-transplant toxicities showed a 1-year cumulative incidence of acute graft-versus-host disease (GVHD) of 45.7% (95% CI 30.7%–59.5%) and chronic GVHD of 18.5% (95% CI 8.5%–31.5%). At the time of analysis, 27 patients had died, primarily from relapse-related causes (n = 17). The study authors concluded that alternative donor HCT expands access to transplantation without an apparent increase in non-relapse mortality, suggesting that fit patients with NA-ATLL should proceed expeditiously to HCT using any available donor option.

    Key Takeaways

    • Alternative donor allogeneic HCT yielded overall survival (p = 0.601) and progression-free survival (p = 0.376) comparable to matched donor transplantation.
    • In multivariable analysis, independent significant predictors of superior overall survival included lymphomatous disease subtype (HR 0.30, 95% CI 0.10–0.88, p = 0.027; 3-year OS 52.3% vs 22.2% for acute subtype) and a Karnofsky performance score of ≥80 (HR 0.26, 95% CI 0.09–0.73, p = 0.01).
    • Cumulative incidence at 1 year was 45.7% (95% CI 30.7%–59.5%) for acute GVHD and 18.5% (95% CI 8.5%–31.5%) for chronic GVHD, with relapse accounting for 17 of the 27 patient deaths.
    Read the original sourceTransplantation and cellular therapy